Evofem Biosciences, Inc.

OTCPK:EVFM Stock Report

Market Cap: US$1.1m

Evofem Biosciences Past Earnings Performance

Past criteria checks 0/6

Evofem Biosciences has been growing earnings at an average annual rate of 58.7%, while the Pharmaceuticals industry saw earnings growing at 10.7% annually. Revenues have been growing at an average rate of 19.2% per year.

Key information

58.73%

Earnings growth rate

83.89%

EPS growth rate

Pharmaceuticals Industry Growth5.95%
Revenue growth rate19.15%
Return on equityn/a
Net Margin-30.46%
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Seeking Alpha • Jul 21

Evofem partners with a360 Media to support Phexxi prescription growth

Evofem Biosciences (NASDAQ:EVFM) is up 6.3% premarket after the firm entered in a pact with  a360 Media. The pact with a360 Media delivers Phexxi branded content in leading entertainment and lifestyle magazines and websites in the U.S. a360 Media's brands include US magazine, InTouch Weekly, and Woman's World. After the first two weeks of the partnership, there was 16% lift in new Phexxi prescriptions.
Seeking Alpha • Jul 12

Evofem announces peer-reviewed publication on birth control method

The shares of Evofem Biosciences (WVFM), a biopharma focused on women’s sexual and reproductive health gained in the pre-market Tuesday on above average volume after the company announced a peer reviewed publication of an article on its Phexxi birth control method. More than 31.4M Evofem (NASDAQ:EVFM) shares have changed hands so far, compared to the 65-day average of 26.9M. The article published on the Journal of Therapeutic Advances in Reproductive Health defines and reconfirms the mechanism of action of Phexxi, an FDA-approved, contraceptive vaginal gel available on prescription. The article highlights how Phexxi prevents pregnancy given its ability to maintain vaginal pH up to an hour before and during vaginal intercourse. Since the recent Supreme Court ruling on abortion rights, Evofem (EVFM) has nearly tripled in value, as shown in this graph.
Seeking Alpha • Jul 06

Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier

Evofem Biosciences focuses on women's sexual and reproductive health and recently developed Phexxi, a non-hormonal female contraceptive. CEO Saundra Pelletier discusses investing implications of the Roe v Wade reversal. Breaking down EVFM’s strong growth rating despite poor profitability and momentum scores according to Seeking Alpha’s Quant system. The interview was recorded on June 16th, 2022 (Roe v Wade was overturned on June 24th, 2022). Evofem Biosciences (NASDAQ: EVFM) is a pharmaceutical company that developed Phexxi,a non-hormonal female contraceptive. EVFM’s stock price increased two-fold following the reversal of Roe v Wade. CEO Saundra Pelletier joined us to discuss the financial and ethical implications of the Roe v Wade reversal. We also break down EVFM’s very strong growth rating, despite its poor profitability and momentum scores according to Seeking Alpha’s Quant system. Plans to cash-break-even by 2023 and profitability by 2024. Opportunities for global licensing made possible by the FDA’s recent extension of Phexxi’s shelf-life.
Seeking Alpha • Jun 30

Evofem announces U.S. patent win for birth control method

Commercial-stage pharma Evofem Biosciences (NASDAQ:EVFM) announced on Thursday that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a certain patent application filed by the company for Phexxi birth control method. The application titled "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides" relates to the composition of matter of the FDA-approved contraceptive vaginal gel, the company said. A patent for the application 16/738,868 is expected to provide protection for Phexxi into 2033, Evofem (EVFM) noted. “….this allowance further solidifies the investment Evofem has made in creating Phexxi and providing it to women across the United States," remarked Evofem (EVFM) Chief Executive Saundra Pelletier. Evofem (EVFM) shares surged on Tuesday after the company announced a partnership with one of the largest pharmacy benefit managers for Phexxi.
Seeking Alpha • Jan 18

Evofem: ACA Coverage Of Phexxi Is A Game Changer

EVFM received what I believe to be incredibly important news last week. That news, which I discuss in depth below, should mean rapidly increasing sales of Phexxi. But the news doesn't only bode well for future sales, it also should also allow the company to realize much higher margins on those sales.

Revenue & Expenses Breakdown

How Evofem Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:EVFM Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2620-6172
31 Dec 2520017-3
30 Sep 2518-620-3
30 Jun 2517-620-3
31 Mar 2517-321-4
31 Dec 2419-9212
30 Sep 2417-11213
30 Jun 241857223
31 Mar 241647243
31 Dec 231850273
30 Sep 231444313
30 Jun 231567438
31 Mar 2318-485715
31 Dec 2217-787225
30 Sep 2220-1199232
30 Jun 2216-28311035
31 Mar 2211-19212236
31 Dec 218-20613833
30 Sep 215-19413830
30 Jun 213-15012425
31 Mar 212-16911020
31 Dec 200-1428717
30 Sep 200-1146614
30 Jun 200-985316
31 Mar 200-814018
31 Dec 190-803122
30 Sep 190-822728
30 Jun 190-872732
31 Mar 190-753139
31 Dec 180-1263443
30 Sep 180-1313345
30 Jun 180-1882741
31 Mar 180-1721833
31 Dec 170-1091224
30 Sep 170-1031117
31 Dec 160-691515

Quality Earnings: EVFM is currently unprofitable.

Growing Profit Margin: EVFM is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: EVFM is unprofitable, but has reduced losses over the past 5 years at a rate of 58.7% per year.

Accelerating Growth: Unable to compare EVFM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EVFM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-4.8%).

Return on Equity

High ROE: EVFM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 04:56
End of Day Share Price 2026/07/06 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Evofem Biosciences, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
John TannerCantor Fitzgerald & Co.
Raghuram SelvarajuH.C. Wainwright & Co.
I-Eh JenLaidlaw & Company (UK) Ltd